SAB Biotherapeutics (SABS) Change in Accured Expenses (2020 - 2026)

SAB Biotherapeutics (SABS) has 7 years of Change in Accured Expenses data on file, last reported at -$1.2 million in Q1 2026.

• Quarterly Change in Accured Expenses fell 304.94% year-over-year to -$1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$836515.0 (down 189.77% YoY) and the FY2025 annual result came in at $941524.0, up 176.48% from the prior year.
• Change in Accured Expenses eased to -$1.2 million in Q1 2026, from -$394856.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $1.9 million in Q3 2024 to a low of -$2.0 million in Q2 2022.
• A 5-year average of -$337477.3 and a median of -$394856.0 in 2025 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2025 — Change in Accured Expenses jumped 1661.16% — and 2026, when it plunged 304.94%.
• Tracing SABS's Change in Accured Expenses over 5 years: stood at -$320231.0 in 2022, then surged by 538.06% to $1.4 million in 2023, then slumped by 202.66% to -$1.4 million in 2024, then surged by 72.58% to -$394856.0 in 2025, then slumped by 202.63% to -$1.2 million in 2026.
• The last three Change in Accured Expenses figures came in at -$1.2 million (Q1 2026), -$394856.0 (Q4 2025), and -$287490.0 (Q3 2025), per Business Quant data.